Summer Sale
50% off Premium Yearly
NASDAQ:AMGN
Amgen Inc. (AMGN)
Financials 
Technical Analysis 
Jun 15, 2026, 12:00 amThis summary was created by AI, based on 20 opinions in the last 12 months.
Amgen Inc. is generally perceived as a well-managed and innovative biotech company, characterized by a strong portfolio with 15 products witnessing double-digit revenue growth. Analysts note the company's potential due to its attractive valuation, with a forward P/E ratio under 20x and a solid dividend yield around 3.23% to 3.46%. Investors are optimistic about Amgen's development of its GLP-1 drug, which is currently in phase 3 testing and has the potential to be a game-changer in the weight-loss market. Despite facing some challenges, including trial misses and growing competition, many experts recommend holding or buying shares, highlighting its safety as a large-cap biotech investment. Overall, Amgen is seen as a stable choice for investors looking for exposure to the biotech sector amidst a fluctuating healthcare market.
He bought it last week to diversify and get more exposure in pharmaceuticals. They report next week. Compare to Abbvie which just surprised with drug sales. There's some FT overhang, but shares have been bottoming out recently. If they announce good results, investors will chase this next week.
Gordon Reid
Andrew PyleAndrew Pyle;fill-opacity:1;'/%3e%3cpath%20d='M31%2018.6001V30H8V18.6001L14.1334%2022.4334L19.4999%2014L24.8669%2022.4334L31%2018.6001Z'%20fill='%23EE5432'%20style='fill:%23EE5432;fill:color(display-p3%200.9340%200.3310%200.1956);fill-opacity:1;'/%3e%3c/svg%3e){kind=small}
Premium content
Premium content
Brian Acker, CAPremium contentAndrew Pyle
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20scale(-1,%201)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
A long-term fine business and just reported good earnings. It's not in tech or industrials, so it has more stickiness. They made positive plans in their drug pipeline. Seasonally, now is the right time to buy biotech
(Analysts’ price target is $256.05)